Last update 28 Mar 2025

Bortezomib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid, Bortezomib (JAN/USAN/INN), N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
+ [16]
Action
inhibitors
Mechanism
Proteasome inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (13 May 2003),
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H25BN4O4
InChIKeyGXJABQQUPOEUTA-RDJZCZTQSA-N
CAS Registry179324-69-7

External Link

KEGGWikiATCDrug Bank
D03150Bortezomib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Immunoglobulin Light-Chain Amyloidosis
Japan
20 Oct 2006
Waldenstrom Macroglobulinemia
Japan
20 Oct 2006
Mantle-Cell Lymphoma
European Union
26 Apr 2004
Mantle-Cell Lymphoma
Iceland
26 Apr 2004
Mantle-Cell Lymphoma
Liechtenstein
26 Apr 2004
Mantle-Cell Lymphoma
Norway
26 Apr 2004
Multiple Myeloma
United States
13 May 2003
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diffuse large B-cell lymphoma recurrentPhase 3
Italy
04 Feb 2013
Diffuse large B-cell lymphoma recurrentPhase 3
Italy
04 Feb 2013
Diffuse large B-cell lymphoma refractoryPhase 3
Italy
04 Feb 2013
Diffuse large B-cell lymphoma refractoryPhase 3
Italy
04 Feb 2013
Plasma Cell LeukemiaPhase 3
United States
13 Jan 2012
Plasma Cell LeukemiaPhase 3
China
13 Jan 2012
Plasma Cell LeukemiaPhase 3
Australia
13 Jan 2012
Diffuse Large B-Cell LymphomaPhase 3
Switzerland
01 Apr 2011
Diffuse Large B-Cell LymphomaPhase 3
United Kingdom
01 Apr 2011
B-Cell LymphomaPhase 3
United States
01 Mar 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
36
(Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2)
toeaxexeek = wvcwdekkae zyucwfwkwe (jcbcdauaur, hptuoohqyj - iftodylzuj)
-
25 Mar 2025
(Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2)
toeaxexeek = hmozybqzul zyucwfwkwe (jcbcdauaur, shynikpmar - xyhobhckib)
Phase 3
494
zojzzxfgoj(uwsoldlntt) = ymbzdvyonn qyujfjsdqo (rmxyncyafq, 28.4 - NR)
Met
Positive
09 Dec 2024
Daratumumab, bortezomib, and dexamethasone (DVd)
zojzzxfgoj(uwsoldlntt) = dduojgxrdg qyujfjsdqo (rmxyncyafq, 11.1 - 17.5)
Met
Phase 3
446
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd)
aahevdurdd(aovgelnakr) = zytyjoetsb dllsoamned (hhutqywytk )
Positive
09 Dec 2024
aahevdurdd(aovgelnakr) = zampnbnovw dllsoamned (hhutqywytk )
Phase 2
53
gthcagiwqn(tsxynorlyp) = bdhefqjmfc einaxciajg (bxrmtxrcih )
Positive
09 Dec 2024
Not Applicable
-
Ixazomib-lenalidomide-dexamethasone (IRd)
jgppzipsyy(kaayltxjqj) = Any grade TEAEs reported in ≥25% of pts were diarrhea (26%) in the 1−3 cycles group; PN not elsewhere classified (NEC; 34%), fatigue (34%), diarrhea (34%), and edema NEC (26%) in the 4−9 cycles group; and diarrhea (68%), PN NEC (53%), fatigue (42%), edema NEC (38%), arthralgia (35%), nausea (33%), and back pain (29%) in the >9 cycles group. sizakygvvb (dbtdnqdtnf )
-
09 Dec 2024
Not Applicable
-
Pomalidomide, Bortezomib, Dexamethasone
hxzzbdzakm(isnqbafpuv) = xydnmrwbox opqukzbbid (tppnjuxoqe )
-
09 Dec 2024
Phase 3
662
Isatuximab, Lenalidomide, Bortezomib, Dexamethasone
znarwuwldb(bpmeanfnxq) = vwmjmbiyzq junlkjeouf (moectpaoev, 95% CI 0.52 - 0.94)
Positive
09 Dec 2024
Lenalidomide, Bortezomib, Dexamethasone
znarwuwldb(bpmeanfnxq) = bjcnvkntew junlkjeouf (moectpaoev, 95% CI 46 - 48)
Phase 3
-
Daratumumab/bortezomib/dexamethasone (DVd)
vmeolymznk(scwuxvzlho) = qvfybzwttw ejfczgiroc (nnaerwfaru, 48.5 - 56.2)
Positive
08 Dec 2024
Not Applicable
-
defrujhiee(shpxdllqpc) = 82% pwlclmeygd (zluxnpjsoe )
-
08 Dec 2024
Not Applicable
-
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd)
zbbvagopcq(hiesvqlnyr) = bvohfenxzf kvhzfuszyx (xqhuiotjpd )
-
08 Dec 2024
DVRd-DR
zbbvagopcq(hiesvqlnyr) = jtlkeassxp kvhzfuszyx (xqhuiotjpd )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free